The high (I)COSt of costimulation for exhausted T cells
ICOS agonists are being investigated for cancer immunotherapy based on the idea that they will reinvigorate exhausted CD8+ T cell anti-cancer immunity. Humblin et al. unexpectedly find the opposite—that CD8+ T cell-intrinsic ICOS expression restrains r…